| Santmyer, JoAnn |
NCT03642067: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer |
|
|
| Completed | 2 | 59 | US | Nivolumab, OPDIVO, BMS-936558, anti-PD-1, Relatlimab, BMS-986016, anti-LAG-3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma | 02/24 | 09/24 | | |
NCT06205836: Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 22 | US | Cemiplimab, REGN2810, LIBTAYO, Fianlimab, REGN3767 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals | Colorectal Cancer | 05/28 | 05/28 | | |
NCT04209686: Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Paclitaxel, Taxol, Olaparib, Lynparza, Pembrolizumab, MK-3475; Keytruda | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Advanced Gastric Adenocarcinoma | 04/28 | 04/28 | | |
NCT03607890: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor |
|
|
| Recruiting | 2 | 42 | US | Nivolumab, anti-PD-1, OPDIVO, Relatlimab, BMS-986016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI) | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | 10/25 | 10/25 | | |
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer |
|
|
| Completed | 2 | 25 | US | INCMGA00012 (PD-1 antibody), MGA012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI) | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 08/24 | 12/24 | | |
NCT04753879: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
|
|
| Recruiting | 2 | 38 | US | Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Metastatic Pancreatic Cancer | 12/25 | 12/29 | | |
NCT05604560: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer |
|
|
| Recruiting | 2 | 25 | US | Tislelizumab, BGB-A317, SX-682 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, BeiGene, Syntrix Biosystems, Inc. | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT06001658: Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers |
|
|
| Recruiting | 2 | 27 | US | Gemcitabine, Cisplatin, Pembrolizumab, KEYTRUDA; anti-PD-1 mAb | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Pancreatic Cancer | 06/28 | 06/28 | | |
NCT03767582: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. |
|
|
| Completed | 1/2 | 46 | US | Stereotactic Body Radiation (SBRT), Nivolumab, OPDIVO, CCR2/CCR5 dual antagonist, BMS-813160, GVAX, PANC 10.05 pcDNA-1/GM-Neo vaccine, PANC 6.03 pcDNA-1/GM-Neo vaccine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 09/24 | 09/24 | | |
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors |
|
|
| Recruiting | 1/2 | 1130 | US | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Revolution Medicines, Inc. | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 05/27 | 07/27 | | |
NCT06027086: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) |
|
|
| Recruiting | 1/2 | 27 | US | Durvalumab, IMFINZI, DRP-104 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dracen Pharmaceuticals, Inc., Fibrolamellar Cancer Foundation | Fibrolamellar Hepatocellular Carcinoma | 08/28 | 08/29 | | |
NCT06411691: KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer |
|
|
| Recruiting | 1 | 50 | US | KRAS Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Balstilimab, AGEN2034, Botensilimab, AGEN1181 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Agenus Inc., Private Philanthropic Funds, National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 11/27 | 11/27 | | |
IRB00210915, NCT04117087: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | US | KRAS peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY® | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 08/25 | 08/25 | | |
| Harper, Emily |
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis |
|
|
| Recruiting | 3 | 156 | US | Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™) | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc. | Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 10/26 | 10/29 | | |
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors |
|
|
| Recruiting | 1/2 | 1130 | US | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Revolution Medicines, Inc. | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 05/27 | 07/27 | | |
| Recruiting | N/A | 1050 | Europe, US | Guardant Reveal | Guardant Health, Inc. | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 02/28 | 02/28 | | |
| Castellano, Asami |
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors |
|
|
| Recruiting | 1/2 | 1130 | US | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Revolution Medicines, Inc. | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 05/27 | 07/27 | | |
